Skip to content
MarketScale
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Health systems are partnering up without changing who owns the hospital

Health systems are partnering up without changing who owns the hospital

Health systems are choosing alliances over mergers, per a July McDermott Will & Schulte analysis and four July deals tracked by Becker's Hospital Review. St. Christopher's, Nemours, Jefferson and Temple signed a nonbinding alliance letter; Palomar UC San Diego Health launched July 1. Ownership stays put; governance, purchasing and outpatient investment absorb the change.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Telemedicine in eye care stops at the retinal scan unless imaging moves home

Telemedicine in eye care stops at the retinal scan unless imaging moves home

An Ophthalmology Times commentary by T.Y. Alvin Liu, Ferdinand Hui and Phillip Phan sorts eye patients into three telemedicine tiers by clinical need. Patients needing regular OCT scans benefit less unless a home device can send the image. Video tools already sit inside Epic and Cerner; the deciding purchase for retina clinics is the imaging device in the patient's living room.

  • 01The dividing line for eye telemedicine is imaging, not video: patients who need regular OCT scans benefit less from remote visits unless a device at home can send the scan, so a video license alone shifts few of those encounters.
  • 02The provider-side requirement, a HIPAA-compliant secured video platform, was already built into Epic and Cerner by 2020; the patient-side requirements (1.5 MB up and down bandwidth, a quiet private room, comfort with the technology) sit outside the health system's control and are the ones worth screening for at scheduling.
  • 03Self-administered home color fundus photography for tracking non-proliferative diabetic retinopathy was named as the nearer route into retina telemedicine; home OCT for wet AMD is the harder gate and the device to watch.

Sep 19, 2026

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512